Navigation Links
Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
Date:10/5/2009

idates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                          Media
    info@peregrineinc.com                              Barbara Lindheim
    (800) 987-8256                                     (212) 918-4650

SOURCE Peregrine Pharmaceuticals, Inc.


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... June 03, 2015 Marktech Optoelectronics is ... Photodiodes. Marktech APD’s have an internal gain mechanism, fast ... the near infrared region. These APD’s are recommended for ... is needed to overcome high pre-amp noise. In addition, ... and are ideal for extreme low-level light detection and ...
(Date:6/2/2015)... , June 2, 2015 TapImmune, Inc. (OTCQB: ... institutional investors have reached an agreement whereby the institutional ... term warrants to provide the Company up to $4.93M ... effective S-1 registration statement. Under the restructured terms and ... call additional warrants which could result in a larger ...
(Date:6/2/2015)... NEW YORK , Jun. 02, 2015 /PRNewswire/ ... "Company"), a diversified life sciences company with interests ... a proprietary synthetic biology platform technology, today announced ... to Typenex Co-Investment, LLC ("Typenex") in exchange for ... January 16, 2015, the Company and Typenex entered ...
(Date:6/2/2015)... June 02, 2015 Cirrascale ... blade-based and rackmount computing and storage infrastructure for ... launch of its high density scale-out, two-in-one video ... Slipstream™ RM1622D . The high density, two-in-one system ... product family with Intel® Iris™ Pro graphics P6300 ...
Breaking Biology Technology:Marktech Introduces New Line of APDs 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 2TapImmune Announces Agreement To Facilitate Near Term Capital Infusion; Expediting Path Toward Phase II Trial Initiation 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 2Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 3Tauriga Sciences, Inc. Extinguishes All Further Obligations to Typenex Co-Investment LLC with One-Time Cash Payment of $230,000 USD 4Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 2Cirrascale® Announces Support for Intel® Xeon® Processor E3-1200 v4 Product Family; Launches Server Offering Optimized for Low Cost-per-Stream Transcoding Applications 3
... NimbleGen Systems , a manufacturer of gene chips for ... offering of stock following its acquisition by Roche , ... to raise $75 million in the IPO, but under the ... Roche will acquire 100 percent of the privately held NimbleGen ...
... - Paul Schneider, a director for the Green Bay-based ... to the board of TrafficCast International , a ... National, Schneider is responsible for new business development and ... , ,Schneider is a long-haul trucking company and a ...
... - Madison and 12 other cities will share a ... Energy as part of the DOE's 2007 Solar America ... a $60 million DOE solar energy program announced ... two-year projects that are designed to integrate solar technologies into ...
Cached Biology Technology:NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 2NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 3NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 4
(Date:5/19/2015)... Sweden , May 18, 2015 ... fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one ... from June until and including Q3 2015 and the sensors ... . Communicated order values for 2015 hereby amount to ... for Q1 2015 of 140 MSEK and a number of ...
(Date:5/18/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... access publishing program that offers immediate publication followed by ... after publication. Following recent approval by the National Library ... this peer review process will now be listed in ... F1000Research ,s acceptance by the NLM Selections group ...
... Health, science and genetics reporters are invited to register ... Genomics (ACMG) Annual Clinical Genetics Meeting, March 19-23, 2013 ... Whole Genome/Exome Sequencing, the focus of the ACMG Meeting ... in healthcare today and in the future. The conference ...
... A new method of establishing hair and eye colour from ... from ancient human remains, finds a new study published in ... HIrisPlex DNA analysis system was able to reconstruct hair and ... the Polish General Wladyslaw Sikorski (1881 to 1943) confirming his ...
Cached Biology News:
...
... a powerful tool for sample purification in ... DNA/RNA or protein purification as well as ... automated on the Genesis Series of instruments ... combination with the RoMa arm and Tecans ...
... filters suitable for use in the Microsart e.motion ... each filter, in a specially designed individual package ... of the band of membrane filter units ensures ... shape of the sealed band guarantees uniform dispensing ...
...
Biology Products: